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Abstract 
Carvedilol (CV) has been used for the management of heart failure, hypertension and 
coronary artery diseases. However, it presents low oral bioavailability (25-35%).  The 
objective of this study was to develop carvedilol-loaded nanocapsules (NC) in order 
to achieve a controlled drug release aiming the development of dosage forms to be 
administered by alternative routes. Poly(ε-caprolactone) (PCL) and Eudragit RS100 
(EUD) were evaluated as polymeric wall. Nanocapsules (CV-PCL-NC and CV-EUD-
NC) were prepared by interfacial deposition of preformed polymer method and 
characterized according to particle size and polydispersity, zeta potential, pH, drug 
content, encapsulation efficiency, morphology, backscattering analysis, presence of 
nanocrystals and drug release profile. Thermal analysis was performed to evaluate 
compatibility between CV and excipients. All formulations showed nanometric 
diameters with low polydispersity and pH slightly acid. The zeta potential was positive 
and negative for CV-EUD-NC and CV-PCL-NC, respectively. The drug content was 
close to theoretical value (0.5 mg.mL-1) for both formulations and the encapsulation 
efficiency was higher than 87% and 99% for CV-EUD-NC and CV-PCL-NC, 
respectively. Nanocapsules were spherical-shaped and their suspensions showed no 
significant phenomena of physical instability. Drug release was controlled by both 
developed formulations. However, CV-PCL-NC showed phase separation during 
storage and an interaction between the drug and the surfactant was evidenced by 
thermal analysis. This study demonstrated the feasibility to encapsulate CV in 
nanocapsules to achieve a controlled release rate. Further studies will be carried out 
to explore alternatives routes of administration using these formulations. 
Keywords: Carvedilol, nanocapsules, Eudragit RS100, poly(ε-caprolactone), drug 
release. 
  
1. INTRODUCTION 
Cardiovascular diseases represent an important public health problem in worldwide. 
They are the major cause of morbidity and mortality, and correspond to the highest 
costs in health care1. Carvedilol (CV) is a drug with a cardiovascular multiple-action. 
It is a non-selective β-adrenoceptor antagonist, α1-adrenoceptor blocker and also 
has antioxidant effects2. Randomized, double-bind studies have been showed that 
CV reduces the morbidity and mortality in patients with mild-to-severe heart failure3-5. 
The blocking effects at vascular α1 receptors, actions on vascular smooth muscle 
and on calcium channels contribute to its blood pressure-lowering effects; therefore 
this drug has been used for the treatment of hypertension6-8. Furthermore, CV may 
be useful in the management of coronary artery diseases like demonstrated in 
experimental models in which it showed an inhibition of the progression of 
atherosclerosis2,9,10. 
CV is a water-insoluble and its systemic bioavailability is just 25-35% due to its low 
dissolution in the intestinal tract, extensive first-pass metabolism and P-glycoprotein 
activity11-14. The encapsulation of active molecules in carrier systems in nanoscale 
can be a good alternative to improve the bioavailability of drugs. In this way, some 
formulations based on CV nanoencapsulation have been developed, such as self-
nano-emulsifying drug delivery systems15,16  and solid lipid nanoparticles17,18. 
Mahmoud et al (15), developed self-nanoemulsifying tablets of CV containing 
excipients with P-glycoprotein inhibition activity aiming a decrease of CV efflux and 
consequently an increase of its intestinal absortion. Singh et al (16) produced self-
nano-emulsifying drug delivery system of CV with potential to enhance the 
biovailability of this drug by facilitating its transport via lymphatic circulation. Shan et 
al (17) prepared tablets containing carvedilol-loaded solid lipid nanoparticle that 
  
protected CV from acid environment. They suggested that carvedilol-loaded solid 
lipid nanoparticles could penetrate in the lymphatic system, avoiding the first pass 
metabolism. Venishetty et al (18) designed carvedilol-loaded solid lipid nanoparticles 
and demonstrated by in vivo study an increase in the oral bioavailability of CV when 
compared with CV suspension. Another important advantage of the nanotechnology 
is that it allows developing innovative dosage forms to be administered by different 
routes of administration19,20. It is suggested by Saindame et al (21) the nasal route of 
CV administration. They developed an in situ gelling nasal spray formulation of CV 
nanosuspension and demonstrated by in vivo pharmacokinetic studies that the 
bioavailability of in situ nasal spray formulation was significantly increased as 
compared to oral administration. 
Usually, medicines containing CV are administrated twice-daily for management of all 
diseases that it is indicated22. Some studies analyzed the pharmacokinetics profiles 
of immediate release formulations of CV administrated twice-daily and controlled-
release formulations of CV administrated once-daily. Their results demonstrated 
similar pharmacokinetics profiles for both formulations22,23, indicating that once-daily 
administration can be as effective as twice-daily administration when the drug is 
administrated by a controlled release approach. Moreover, the reduction of drug 
administration can improve patient adherence, quality of life, hospital utilization and 
potentially favorable effects24. The nanotechnology show promises on the 
development of systems with controlled and sustained drug-release properties25. 
Up to now, to the best of our knowledge, no reports of the encapsulation of CV in 
polymeric nanocapsules aimed to achieve a controlled release rate have been 
published. Polymeric nanocapsules are a type of nanoparticles in which the drug is 
confined to a cavity surrounded by a polymeric wall. They present high physical 
  
stability and the ability to control the release of drugs26-29. Recently, our research 
group developed a new kind of nanocapsules named lipid core-nanocapsules, which 
are composed by a dispersion of sorbitan monostearate and medium chain 
triacylglycerol, in the core, surrounded by poly(ε-caprolactone) (PCL), as polymeric 
wall30. PCL offers the advantages of being a biodegradable and biocompatible 
polymer for application of drug delivery system31. Another polymer which can be 
used as nanocapule wall is Eudragit RS100 (EUD), a co-polymer of 
poly(ethylacrylate, methyl–methacrylate). It is easy to fabrication, has low cost and a 
good stability, representing a good material for preparation of controlled-release drug 
delivery systems32,33.  
In this scenario, our work aims to develop carvedilol-loaded nanocapsules prepared 
with two different polymers and to evaluate their potential to control the in vitro CV 
release profile, as suitable nanocarriers for the development of dosage forms for 
administration of CV by alternative routes of administration, like the pulmonary, nasal 
and subcutaneous routes. 
 
2. METHODS 
2.1. Materials 
Carvedilol was obtained from Henrifarma (São Paulo, Brazil). Poly(ε-caprolactone) 
(MW 80,000) and sorbitan monostearate (Span 60®) were acquired from Sigma-
Aldrich (São Paulo, Brazil). Eudragit RS100 was supplied from Degussa (Darmstadt, 
Germany) and grape seed oil from Dellaware (Porto Alegre, Brazil). Polysorbate 80 
and acetone were purchase from Vetec (Rio de Janeiro, Brazil). HPLC grade 
acetonitrile was purchased from Tedia (Rio de Janeiro, Brazil). 
2.2. Preparation of nanocapsules suspensions 
  
Nanocapsules were prepared by interfacial deposition of preformed polymer 
method34,35. For the preparation of EUD nanocapsules (CV-EUD-NC) an organic 
phase was prepared dissolving 0.1 g of polymer (EUD), 165 µL of grape seed oil and 
5 mg of CV (0.5 mg.mL-1) in 27 mL of acetone under magnetic stirring at 40°C. For 
the preparation of PCL nanocapsules (CV-PCL-NC) the organic phase was prepared 
dissolving 0.1 g of polymer (PCL), 165 µL of grape seed oil, 0.0385 g of sorbitan 
monostearate and 5 mg of CV (0.5 mg.ml-1) in 27 mL of acetone under magnetic 
stirring at 40°C. Each organic phase was injected into 53 mL of an aqueous phase 
containing 0.077 g of polysorbate 80 under magnetic stirring at 40°C temperature. 
After, acetone was eliminated and the suspension concentrated under reduced 
pressure (Rotavapor R-114, Buchi, Flawil, Switerzland) until final volume of 10 mL. 
Blank formulations were also prepared omitting the drug (BL-EUD-NC or BL-PCL-
NC). The proportion of components used was based in the study of Venturi et al (35), 
which demonstrated the better concentration of components to obtain exclusively 
nanocapsules. All formulations were prepared in triplicate of batches, stored at room 
temperature (25 ± 2 ºC) and protected from light. 
2.3. Analitycal method 
Assay of CV was carried out by High Performance Liquid Chromatography (HPLC), 
using a method adapted from Ieggli et al (36) and validate according to our purposes. 
The analyzes were performed on a Shimadzu LC system (Kyoto, Japan) equipped 
with a CBM-20A system controller, LC-20AT pump, DGU-20A5 degasser, SIL-20A 
auto-sampler and a SPD-20AV. A Phenomenex Luna C18 column (250 mm x 4.6 mm 
I.D., with a particle size of 5 µm) with a C18 guard-analytical column was utilized. The 
mobile phase was composed of phosphoric acid solution pH 3.0/acetonitrile (50:50, 
v/v), run at a flow rate of 0.8 mL.min-1 and detection wavelength of 241 nm. The run 
  
time was 10 minutes. Calibration curves (n =3) were built to assay the concentration 
of the drug in the samples. For drug loading and encapsulation efficiency an injection 
volume of 10 µL was used. The method demonstrated good linearity (r = 0.9998) in 
the range of 1.00 - 20.00 µg.mL-1. For drug release studies 20 µL of injection volume 
were used and it presented linearity (r = 0.9969) in the range of 0.5 – 12.5 µg.mL-1. 
Besides, specificity was evaluated by injecting samples prepared with the blank 
formulations. Intraday (n=6) and interday (n=9) precision were also evaluated 
according to the official guidelines37,38, showing relative standard deviation below 
2.0%. 
2.4. Physicochemical characterization 
2.4.1. Particle size and polydispersity  
The mean particle size of suspensions was determined by three complementary 
methods: laser diffraction (LD) (Mastersizer 2000, Malvern Instruments Ltd., UK), 
dynamic light scattering (DLS) (ZetaSizer Nano ZS, Malvern Instruments Ltd., UK) 
and nanoparticle tracking analysis (NTA) (NanoSightR NTA LM 10v2, Amesbury, 
England). The volume-weighted mean diameters (D4,3) and polydispersity (Span) 
were analyzed by LD inserting the sample directly into the compartment disperser. 
Mean particle size and polydispersity index (IPD) were checked by DLS after dilution 
of the suspensions (20 µL) in 10 mL of water previously filtered with hydrophilic 
membrane (0.45 µm, Millipore®). The NTA method is based on a laser illuminated 
microscopical technique and particles are visualized and analyzed in liquid 
dispersions39. This analysis was performed exclusively for drug-loaded 
nanocapsules. The CV-EUD-NC were diluted 2,500 x and CV-PCL-NC was diluted 
10,000 x, both with water previously filtered with hydrophilic membrane (0.45 µm, 
Millipore®), and were measured for 60 s with automatic detection at room 
  
temperature (25 ºC). For laser diffraction and dynamic light scattering the samples 
were analyzed in triplicate of batches (n = 3). 
2.4.2 Zeta potential 
Zeta potential was determined (n=3) by electrophoretic mobility on a ZetaSizer Nano 
ZS (Malvern Instruments Ltd., UK). The samples (20 µL) were diluted in 10 mL of 10 
mM NaCl solution previously filtered with hydrophilic membrane (0.45 µm, Millipore®).  
2.4.3. pH measurements 
The measurement of pH was realized by potentiometry using a calibrated 
potentiometer (VB-10, Denver Instrument, USA) directly in the formulations. All 
samples were analyzed in triplicate (n = 3). 
2.4.4. Transmission electron microscopy 
The morphology of CV-EUD-NC and CV-PCL-NC was observed by transmission 
electron microscopy (TEM, Jeol JEM 1200-ExII, 100 mV, Tokyo, Japan) at Centro de 
Microscopia Eletrônica (UFRGS, Brazil). The samples were diluted (1:10 v/v) in 
purified milli-Q water, deposited on specimen grid (Formvar-Carbon support film, 
Electron Microscopy Sciences) and negatively stained with uranyl acetate solution 
(2%, w/v)40. 
2.4.5. Drug content and encapsulation efficiency 
The drug was assayed by HPLC after dissolution of 1.0 mL of suspensions in 10 mL 
of acetonitrile followed by 10 minutes of sonication. This dispersion was centrifuged 
at 5000 rpm for 10 min. After, an aliquot of 2.0 mL of the supernatant was taken, 
diluted until 10mL in mobile phase and filtered with hydrophilic membrane (0.45 µm, 
Millipore®) prior HPLC analysis. Encapsulation efficiency was calculated (n = 3) by 
the difference between total drug and free drug. The free drug in the ultrafiltrate was 
assayed by HPLC after appropriate dilution with mobile phase. The ultrafiltrate was 
  
obtained by ultrafiltration/centrifugation technique (Ultrafree-MC 10,000 MW, 
Millipore, Billerica, USA) at 5000 rpm during 10 min. 
2.5. In vitro drug release 
The in vitro release of CV from CV-EUD-NC and CV-PCL-NC was carried out by 
dialysis bag method (n = 3). Two milliliters of formulations was placed into a dialysis 
tubing cellulose membrane with flat width of 25mm (Sigma-Aldrich, São Paulo, 
Brasil) and suspended into a becker containing 100 mL of release medium (sodium 
phosphate buffer pH 6,8) previous filtered using a hydrophilic membrane (0.45 µm, 
Millipore®). The samples were maintained in a bath at 37°C under mild agitation. Sink 
condition was maintained during the experiment. At predetermined time intervals, 1.0 
mL of the external medium was withdrawn and directly analyzed by HPLC with the 
method described in section 2.3.6. A CV hydroalcoholic (1:1 v/v) solution (CV-F), at 
the same concentration of nanocapsule suspensions (0.50 mg.mL-1) was also 
prepared to evaluate the diffusion of non-encapsulated CV across the dialysis bag 
(n=3). In order to explore the influence of formulations on drug release profiles, the 
mathematical modeling mono and biexponential (MicroMath® Scientist) were used. 
The best model that described the drug release profile was selected through the 
model selection criteria (MSC), graphic adjustment and correlation coefficient. In 
addition, to investigate the drug release mechanism from nanocapsules it was 
applied the Power Law model, which allows obtaining the parameters a and n, that 
indicate the structural and geometric characteristics of the carriers and mechanism of 
release, respectively. 
 2.6. Multiple light scattering analysis – preliminary stability study 
In order to predict the physical stability of formulations multiple light scattering 
analysis were carried out (Turbiscan LAbR, Formulaction, L’Union, France). This 
  
method can evidence the tendency to occur physical destabilization phenomena 
(creaming, sedimentation, flocculation or coalescence) scanning the samples from 
the bottom to the top of the cuvette. Analyses were performed at 25 °C using 20 mL 
of sample without dilution, over 1 h (one scan every 5 minutes). 
2.7. Differential scanning calorimetry (DSC) analysis 
In order to verify possible interactions between the constituents of formulations, 
thermal analysis was performed using DSC equipment (TA Instruments, model Auto 
Q20, USA). For this, bulk CV and sorbitan monostearate and their physical mixtures 
(at the same proportion used in nanocapsules) were analyzed. Approximately 9 mg 
of samples were placed in aluminum pans and heated from 0 to 300°C with scan 
rates 10 °C.min-1 under a nitrogen atmosphere. These analysis were performed at 
Laboratório Multiusuário de Análise Térmica (LAMAT, UFRGS, Porto Alegre, Brazil). 
2.8. Presence of drug nanocrystals 
For the determination of the presence of drug nanocrystals in CV-EUD-NC, the 
formulation was separated in two different flasks. One flask remained motionless and 
at predetermined time intervals (2, 3, 5, 7 e 15 days) an aliquot was withdrawal from 
the surface of the suspension. The other flask was shacked for completely dispersion 
of particles before each sample collection, at the same time intervals of motionless 
flask41. The drug content in all samples was determined by HPLC (section 2.3.5). 
2.9. Statistical analysis 
Statistical analysis was done by one-way analysis of variance (ANOVA) when three 
or more groups were compared and t test when two groups were compared. 
Difference was considered to be statistically significant at a level of p ≤ 0.05. Data are 
presented as the mean ± standard deviation (SD). 
 
  
3. RESULTS AND DISCUSSION 
3.1. Physicochemical characterization 
After the preparation, all formulations showed milky bluish liquid aspect with Tyndall 
effect. Nanoparticles may be defined as submicron (˂1µm) colloidal systems42 and 
according to European Legislation (2011), products presenting 50 % of particles 
smaller than 100 nm can be considered as nanomaterials. Their size distributions are 
directly affected by qualitative and quantitative composition as well as the preparation 
method. For nanocapsules, one of the determining factors that influence the 
nanoparticle diameter is the nature of the oil that composes their core26. In Table 1, it 
can be observe that all formulations showed particle size distribution exclusively in 
the nanoscale range. Figure 1 shows the granulometric profiles by laser diffraction 
(LD) of the nanocapsules (n = 3).  Independent on the presence of the drug or type of 
polymer, the particle size distributions are unimodal. Furthermore, analyzing the 
number of particles (Figure 1A), 50 % of the particles are smaller than 68 ± 2 nm, 71 
± 3 nm, 75 ± 2 and 63 ± 1 nm for BL-EUD-NC, CV-EUD-NC, BL-PCL-NC and CV-
PCL-NC, respectively, being considered as nanomaterials. The volume-weighted 
mean diameters (D4,3) (Figure 1B) were between 135 and 224 nm. The presence of 
the drug did not affect the particle size profile for EUD nanocapsules, since it was not 
observed significant difference (p>0.05) in D4,3 between CV-EUD-NC and BL-EUD-
NC. On the other hand, the presence of drug led to a significant size reduction 
(p≤0.05) in CV-PCL-NC when compared with BL-PCL-CV. This result could indicate 
some interaction between components of the formulation and the drug. The 
polydispersity (Span) was lower than 2.0 for all formulations showing a homogenous 
size distribution. The hydrodynamic diameters (Z-average) and polydispersity 
indexes (PDI) were measured by dynamic light scattering (DLS). The mean 
  
diameters of all formulations with EUD were similar to those determined by LD 
(p>0.05). However, by this technique we could observe a significant bigger mean 
diameter (p≤0.05) of CV-PCL-NC in relation to the data obtained by LD. The Z-
average of NC-PCL-CV was significant lower (p≤0.05) than BL-PCL-NC confirming 
the result obtained by LD. So, there is an influence of the drug on this parameter. 
Polydispersity indexes determined by DLS were below 0.20, showing a narrow size 
distribution and confirming the results obtained by LD. In order to confirm the results 
of diameters obtained by LD and DLS, drug-loaded nanocapsules (CV-EUD-NC and 
CV-PCL-NC) were analyzed by NTA. This is an innovative technique that tracks 
particles in liquid suspensions through their Brownian motion, and combines the 
advantages of single particle (transmission electron microscopy) and ensemble 
(photon correlation spectroscopy) approaches27,43. The results of NTA were 
compared with the results of each technique (LD or DLS). For CV-EUD-NC, the 
mean diameter determined by NTA was similar (p>0.05) to that determined by DLS, 
but was significantly bigger (p≤0.05) that the values obtained by LD. For CV-PCL-NC 
the mean diameter determined by NTA was significantly bigger (p≤0.05) when 
compared with the other both techniques. In function of the NTA technique be based 
on the tracking of single particles and DLS measure a bulk of particles, it is 
suggested that DLS technique can be more sensible to the presence of small 
amounts of large particles, providing results of bigger mean diameters44. However, it 
was demonstrated by Filipe et al (45) that in some cases the intense light scattering 
by large particles makes the small particles more difficult to be detected and prevents 
some of them from being tracked by the NTA software. This phenomenon could 
explain the data obtained for NTA analyses for CV-PCL-NC.  
  
The zeta potential reflects the surface potential of particles and it is affected by the 
polymer used as constituent of the polymeric wall, whereas it is the main component 
of nanocapsules. As expected, the suspensions produced with EUD as polymer 
exhibited positive zeta potential (Table 2). This value is coherent with the cationic 
nature of the polymer, which contains a quaternary ammonium group46. The positive 
charge was similar to others studies47,48. On the other hand, formulations with PCL 
showed negative zeta potential as a consequence of the non-ionic character of the 
polymer and the presence of polysorbate 80 at the interface particle/water, which has 
a negative surface density of charge due to the presence of oxygen atoms49. Similar 
results were observed in others works50,51.  These values were significantly altered 
by the presence of the drug (p ≤ 0.05). However the stabilization of these particles 
can be explained by a steric mechanism and not by electric repulsion, which depends 
on the surface charge52. The pH values of all formulations were slightly acid (Table 
2), as other nanoparticles prepared with PCL or EUD47,51 . The presence of the drug 
in nanocapsules and the type of polymer used did not influence this parameter (p > 
0.05). 
TEM micrographs demonstrate the spherical shape of nanocapsules and confirm 
their nanometric sizes, whose diameters were in agreement with those determined 
by LD, DLS and NTA (Figure 2). The drug content was close 0.5 mg.mL-1 for both 
nanoparticles [0.47 ± 0.08 mg.mL-1 for CV-EUD-NC and 0.47 ± 0.01 mg.mL-1 for CV-
PCL-NC (Figure 3)]. The encapsulation efficiency was 88 ± 1.10 % for CV-EUD-NC 
and 99.10 ± 0.21 % for CV-PCL-NC. Statistical analysis demonstrated that CV-PCL-
NC has higher drug encapsulation efficiency than CV-EUD-NC (p≤0.05). Hence, both 
developed formulations of nanocapsules exhibited suitable nanoscopic 
  
characteristics, demonstrating the feasibility of CV encapsulation in nanocapsules 
containing a surrounding wall formed by different polymers (EUD or PCL). 
3.2. In vitro drug release 
One of the advantages of nanocarrier systems is their ability to control the drug 
release, which is dependent to desorption of drug from the surface of the particles, 
diffusion through the polymeric wall, erosion of the polymer matrix or the combination 
of processes of diffusion and erosion53. In this work we analyzed the ability of EUD 
and PCL nanocapsules to control the CV, investigating the mechanism underlying 
the drug release. Results of the in vitro drug release study are presented in Figure 4. 
It can be observed that 88.49 ± 2.97 % of the CV diffused from the  hidroalcoholic 
solution (CV-F) in 6 hours, whereas after 24 hours 73.04 ± 3.07% and 49.47 ± 2.51% 
of drug was released from CV-EUD-NC and CV-PCL-NC, respectively. These results 
demonstrated that our nanocapsules were able to retard the drug release. Moreover, 
nanocapsules prepared with PCL (CV-PCL-NC) showing the best control of drug 
release. This better performance on the drug release profile can be related with the 
type of the polymeric wall and/or with the presence of sorbitan monostearate in the 
core of CV-PCL-NC, which is a kind of nanocapsules that are composed by a lipid-
core. Previous studies demonstrated that the viscosity of  this kind of core increases 
with the presence of sorbitan monostearate and consequently decreases the drug 
diffusive flux34.   
The results of drug-release were analyzed by mono and biexponential mathematical 
modeling and the best model that described the drug release profile selected through 
the model selection criteria (MSC), graphic adjustment and correlation coefficient (R) 
was the monoexponential. Comparing the kinetic constants (k) (Table 3), that relates 
the drug release as a function of time, it can be observed that the drug release rate 
  
from CV-PCL-NC was significantly slower (p≤0.05) than from CV-EUD-NC. This 
result confirms the difference on the drug release profile of formulations. Moreover, 
the mechanism of drug release was investigated using the Korsmeyer-Peppas model 
(Power law), which supply the release exponent (n) that can be used to set the 
release mechanism54. CV release from CV-PCL-NC showed regression coefficients 
of 0.9838 ± 0.0111, MSC of 3.13 ± 0.64 and n of 0.52 ± 0.07 whereas CV-EUD-NC 
showed regression coefficients of 0.9436 ± 0.0315, MSC of 1.86 ± 0.56 and n of 0.35 
± 0.01. Using this model, for spherical particles, if the release exponent n is equal to 
0.43 a Fickian diffusion explains the release mechanism; however, if n has a value 
between 0.43 and 0.85 it indicates that the mechanism of drug release is according 
to an anomalous transport54. According to our results, the CV release from CV-PCL-
NC and CV-EUD-NC can be described by two different mechanisms. For EUD 
nanocapsules, CV release was according to a Fickian diffusion behavior, whereas for 
PCL nanocapsules, CV was released by relaxation of the polymer chains as well as 
Fickian diffusion (anomalous transport). These results reinforce the differences of CV 
release when encapsulated in nanocapsules prepared with different polymers. 
Beyond the viscosity of the core, the more uniform arrangement of the PCL can be 
influencing the slower carvedilol release, because PCL has a semi-crystalline 
structure and this may result in more resistance to the drug diffusion and polymer 
relaxation29,55.  
3.3. Multiple light scattering analysis – preliminary physical stability study 
When the zeta potential of nanocapsules is higher than 30 mV (in module) the 
charge repulsion can result in adequate stability. However, these nanostructures can 
be stabilized by other mechanisms than the electric repulsion, as the steric 
stabilization by surfactants and polymeric chains42. In our formulations, the surface of 
  
the polymeric wall is covering by polysorbate 80, which is responsible for their steric 
stabilization35. In order to confirm the physical stability of the formulations, multiple 
light scattering analyses were carried out56. This technique gives information about 
destabilization phenomena as a function of time. In Figure 5 is possible to observe 
the graphical analysis of variations in the backscattering during 1 hour of analysis. No 
variation at the middle of the cell was observed and a small variation (< 2 %) of the 
delta backscattering occurred in bottom and top of cuvettes for both samples. These 
results show that the formulation do not present any tendency for physical instability 
immediately after preparation. However, about three days after the preparation of the 
CV-PCL-NC a visual phase separation was observed. This phenomenon was not 
observed for the same formulation prepared without drug (BL-PCL-NC). In order to 
elucidate the basis of this phenomenon, different formulations were prepared, 
omitting one component of the initial suspension. Two nanoemulsions omitting the 
polymer, containing or not the sorbitan monostearate (NE1 and NE2, respectively) 
were prepared, one formulation omitting the oil (nanosphere, NS) and one 
nanocapsule formulation using sorbitan monooleate instead of sorbitan monostearate 
(NC80) (Table 4). 
Formulations NE1 and NS after some days of preparation showed phase separation. 
The phase separation was not observed for formulation NE2. These results 
suggested that an interaction between the drug and the sorbitan monoestearate 
could explain the physical instability of carvedilol-loaded PCL nanocapsules. In order 
to check this hypothesis, a nanocapsule formulation using sorbitan monooleate 
instead of sorbitan monostearate was prepared. The formulation prepared with 
monooleate sorbitan did not show phase separation, confirming the incompatibility 
between carvedilol and sorbitan monostearate. Analyzing our results we could 
  
suggest that the interaction between sorbitan monostearate and carvedilol in CV-
PCL-NC results in expulsion of the lipophilic surfactant from the core and its 
accumulation in the polymeric wall. As consequence of this, the interaction between 
the nanoparticles and water decreases a lot, resulting in the formation of two phases, 
water and agglomerate of nanocapsules (Figure 6). At this point it is noteworthy to 
mention that these physical instability is reversible, being the two phases easily 
redispersed after stirring. However, this limitation could be probably avoided by the 
conversion of the liquid suspension in dry powder materials using a drying process. 
Lyophilization and spray drying are strategies that have been widely studied in order 
to increase the stability of nanoparticle suspensions57,58.  
3.4. Differential scanning calorimetry (DSC) analysis 
In order to explore the incompatibility between the components of CV-PCL-NC, which 
resulted in phase separation, thermal analyzes were carried out using the DSC 
technique. This technique provides information about physical and energetic 
properties of substances61. It is a rapid method that has been used to investigate the 
compatibility of materials through the appearance, shift, or disappearance of 
endotherms or exotherms peaks62. The DSC thermal curves of CV, sorbitan 
monosteareate and their physical mixture are showed in Figure 7. Individual 
components revealed an endothermic peak at 111.28 °C and 40.78 °C for CV and 
sorbitan monostearate, respectively. For their physical mixture, the thermal curve 
shows the endothermic peak of sorbitan monostearate at the same temperature 
(40.78°C), but the endothermic peak of CV disappeared. This result can suggest a 
formation of a molecular mixture of sorbitan monostearate and CV, showing a poor 
compatibility between these materials and confirming our previous findings about the 
physical instability of CV-PCL-NC containing both components. This result supports 
  
our hypothesis of an expulsion of the molecular mixture (sorbitan monostearate + 
CV) from the core, resulting in the high particle aggregation followed by a phase 
separation. It is noteworthy to mention that this phase separation does only 
happened after three days of storage. All the physicochemical data and drug release 
data were studied using formulation prepared at the same day or in the day before 
the analyses. 
3.5. Presence of drug nanocrystals 
The process of encapsulation of lipophilic drugs in nanocapsules can result in 
simultaneous formation of drug nanocrystals stabilized by surfactant. These 
structures can be simultaneously formed when the drug concentration is higher than 
its saturation in the oily core. As a function of time, these nanocrystals can 
agglomerate and precipitate, consequently the total drug content decreases59,41,60. In 
order to verify the presence of drug nanocrystals in the developed formulations, 
which could have an important role on their stability and drug release profile, 
immobile and shaken samples were analyzed during 15 days. The drug content 
remained constant for both samples (immobile and shaken) after 15 days, indicating 
the absence of drug nanocrystals in CV-EUD-NC formulation. The presence of 
nanocrystals in the formulation CV-PCL-NC was not carried out because of its 
physical instability after three days of storage, which could interfere in the reliability of 
the results. 
 
4. CONCLUSION 
This study demonstrated the feasibility of CV encapsulation in nanocapsules in order 
control its release rate. This behavior can help in the development of dosage forms 
for using CV by alternative routes of administration. Nanocapsules produced with 
  
EUD, as component of polymeric wall, showed spherical, nanometric particle size 
distribution and ability to control the CV release over time. Nanocapsules produced 
with PCL as polymer showed similar characteristics, but showed an early physical 
instability explained by the interaction between the drug and the sorbitan 
monostearate. This interaction imposes a drawback to encapsulate CV in lipid-core 
nanocapsules. Studies to increase the physicochemical stability of this formulation as 
well to explore alternatives routes of CV administration using these formulations are 
under development. 
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Table 1: Particle size distributions and polydispersity indices of Carvedilol-loaded 
Eudragit RS100 nanocapsules (CV-EUD-NC), Carvedilol-loaded poly(ε-caprolactone) 
nanocapsules (CV-PCL-NC), blank Eudragit RS100 nanocapsules (BL-EUD-NC), 
and blank poly(ε-caprolactone) nanocapsules (BL-PCL-NC) by laser diffraction (LD), 
dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA). 
Formulations 
LD DLS NTA 
D(4,3) ± SD 
(nm) 
Span ± SD Z-average ± 
SD (nm) 
IPD ± DP Mean diameter 
(nm) 
CV-EUD-NC 135.3 ± 3.2a 1.21 ± 0.07 139.2 ± 5.6a 0.14 ± 0.005 152 ± 44 
CV-PCL-NC 161.0 ± 4.0a 1.56 ± 0.03 179.6 ± 2.8b 0.08 ± 0.005 210 ± 91 
BL-EUD-NC 162.0 ± 33.4a 1.39 ± 0.33 141.6 ± 8.8a 0.13 ± 0.01 - 
BL-PCL-NC 224.3 ± 18.9
b 1.69 ± 0.03 215.7 ± 8.0c 0.13 ± 0.02 - 
SD = standard deviation (n=3). Means, in column, with the same letter are not 
significant different (p > 0.05, ANOVA). 
 
 
 
 
 
 
 
 
 
 
  
Table 2: Zeta potential and pH of carvedilol-loaded Eudragit RS100 nanocapsules 
(CV-EUD-NC), Carvedilol-loaded poly(ε-caprolactone) nanocapsules (CV-PCL-
NC), blank Eudragit RS100 nanocapsules (BL-EUD-NC), and blank poly(ε-
caprolactone) nanocapsules (BL-PCL-NC). 
Formulations Zeta Potential ± SD 
(mV) 
pH ± SD 
CV-EUD-NC 10.65 ± 0.49a 6.83 ± 0.12a 
CV-PCL-NC -6.63 ± 0.6b 6.85 ± 0.03a 
BL-EUD-NC 3.92 ± 0.8c 5.85 ± 0.01a 
BL-PCL-NC -12.22 ± 0.27d 6.55 ± 0.80a 
SD = standard deviation (n=3). Means, in column, with the same letter are not 
significant different (p > 0.05, ANOVA). 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 3: Observed rate constants (k), correlation coefficients (R) and model selection 
criteria (MSC) obtained by mathematic modeling of CV release from nanocarriers, 
Carvedilol-loaded Eudragit RS100 nanocapsules (CV-EUD-NC) and Carvedilol-
loaded poly(ε-caprolactone) nanocapsules (CV-PCL-NC). 
 CV-EUD-NC CV-PCL-NC 
MSC 0.6531 ± 0.1059 0.9873 ± 0.5910 
R 0.9541 ± 0.0315 0.9764 ± 0.0062 
k (min-1) 0.1170 ±0.0040a 0.0395 ± 0.0012b 
Mean, in line, with different letter are significantly different (p ≤ 0.05, t test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 4: Components of formulations used to evaluate the phase separation 
phenomena. Nanoemulsion without sorbitan monostearate (NE1), nanoemulsion with 
sorbitan monostearate (NE2), nanospheres (NES) and nanocapsules with sorbitan 
monooleate (NC80). 
Formulations PCL 
Grape 
seed oil 
Sorbitan 
monostearate 
Sorbitan 
monooleate 
Carvedilol 
NE1 - 165 µL 0.0385 g - 0.005 g 
NE2 - 165 µL - - 0.005 g 
NES 0.1 g - 0.0385 g - 0.005 g 
NC80 0.1 g 165 µL - 0.0385 g 0.005 g 
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Figure 1: Particle size distributions of Eudragit RS100 nanocapsules (CV-EUD-NC 
and BL-EUD-NC) and poly(ε-caprolactone)  nanocapsules (CV-PCL-NC and BL-
PCL-NC). Graphics A and B show the measurements considering number (%) and 
volume (%) of particles, respectively.   
Figure 2: TEM micrographs:  A (75000x), B (150000x) and C (300000x) CV-EUD-NC; 
D (75000x), E (150000x) and F (300000x) CV-PCL-NC. 
Figure 3: Representative chromatograms obtained in the evaluation of drug content 
of carvedilol-loaded Eudragit RS100 nanocapsules (CV-EUD-NC) (A) and carvedilol-
loaded poly(ε-caprolactone) nanocapsules (CV-PCL-NC) (B).  
Figure 4: In vitro drug release profile from Eudragit RS100 nanocapsules (CV-EUD-
NC) and poly(ε-caprolactone) nanocapsules (CV-PCL-NC) and from hidroalcoholic 
solution (CV-F) by the dialysis bag method (n = 3).  
Figure 5:  Delta backscattering (%) profiles of Eudragit RS100 nanocapsules (CV-
EUD-NC) (A), and poly(ε-caprolactone) nanocapsules (CV-PCL-NC) (B). The bottom 
and top of the cuvette are displayed on the left and right sides of the images.  
Figure 6: Formulation of poly(ε-caprolactone) nanocapsules (CV-PCL-NC) after 
phase separation. 
Figure 7: Thermal curves of Carvedilol (CV), Sorbitan monostearate and their 
physical mixture. 
 
